A Phase III, Open Label, Randomized, Controlled, Multi-Centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy versus Physician's Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutations
This open label, randomised, controlled, multi-centre phase III study will assess the
efficacy and safety of single agent olaparib vs standard of care based on physician''s choice
of capecitabine, vinorelbine or eribulin in metastatic breast cancer patients with gBRCA 1/2
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.